---
title: "Kisqali (ribociclib) in HR-positive HER2-negative advanced or metastatic breast cancer: Safety questions"
description: "Safety questions on Kisqali (ribociclib) in HR-positive HER2-negative advanced or metastatic breast cancer, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Side effects, Warnings, and Monitoring. Questions: What are the most common side effects of Kisqali in metastatic breast cancer? What are the side effects of Kisqali plus letrozole (MONALEESA-2)? What are the side effects of Kisqali plus fulvestrant (MONALEESA-3)? What are the side effects of Kisqali in premenopausal women (MONALEESA-7)? 10 further questions follow. 14 questions quoted from 4 sources."
canonical: "https://www.evicenter.com/medical-information/kisqali--hr-positive-her2-negative-advanced-or-metastatic-breast-cancer/safety"
published: "2026-11-14T00:11:41-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Kisqali (ribociclib) in HR-positive HER2-negative advanced or metastatic breast cancer: Safety questions

Manufacturer: Novartis Pharmaceuticals Corporation  
Prescribing information: [Kisqali](https://www.novartis.com/us-en/sites/novartis_us/files/kisqali.pdf)

Safety questions that apply to every indication of Kisqali are on [Kisqali (ribociclib), all indications: Safety](https://www.evicenter.com/medical-information/kisqali/safety).

## Side effects

<a id="kisqali-side-effects"></a>

### What are the most common side effects of Kisqali in metastatic breast cancer?

Applies to: Patients with HR-positive, HER2-negative advanced or metastatic breast cancer in pooled analyses of MONALEESA-2, MONALEESA-3, and MONALEESA-7

> “In addition, the pooled safety population described in the WARNINGS AND PRECAUTIONS reflects exposure to 
> KISQALI in 1065 patients with advanced or metastatic breast cancer (MONALEESA-2, MONALEESA-3, MONALEESA-
> 7), of whom 76% were exposed for 6 months or longer, and 62% were exposed for greater than one year. The most common 
> (≥ 20%) adverse reactions, including laboratory abnormalities, were leukocytes decreased (95%), neutrophils decreased 
> (93%), hemoglobin decreased (68%), lymphocytes decreased (66%), aspartate aminotransferase increased (55%), gamma-
> glutamyl transferase increased (53%), alanine aminotransferase increased (52%), infections (47%), nausea (47%), creatinine 
> increased (42%), fatigue (35%), platelets decreased (34%), diarrhea (33%), vomiting (29%), headache (27%), constipation 
> (25%), alopecia (25%), cough (24%), rash (24%), back pain (24%), and glucose serum decreased (20%).”

Source: [KISQALI: Prescribing information, page 10, captured 2026-11-13](https://www.novartis.com/us-en/sites/novartis_us/files/kisqali.pdf#page=10)

<a id="kisqali-side-effects-letrozole"></a>

### What are the side effects of Kisqali plus letrozole (MONALEESA-2)?

Applies to: Postmenopausal women with HR-positive, HER2-negative advanced or metastatic breast cancer and no prior therapy for advanced disease, with letrozole (MONALEESA-2)

> “The safety of KISQALI was evaluated in MONALEESA-2, a clinical trial of 668 postmenopausal women receiving 
> KISQALI plus letrozole or placebo plus letrozole [see Clinical Studies (14)]. The median duration of exposure to KISQALI 
> plus letrozole was 13 months with 58% of patients exposed for ≥ 12 months.”

Source: [KISQALI: Prescribing information, page 12, captured 2026-11-13](https://www.novartis.com/us-en/sites/novartis_us/files/kisqali.pdf#page=12)

> “The most common (≥ 20% on the KISQALI arm and ≥ 2% higher than placebo) adverse reactions, including laboratory 
> abnormalities, were neutrophils decreased, leukocytes decreased, hemoglobin decreased, nausea, lymphocytes decreased, 
> alanine aminotransferase increased, aspartate aminotransferase increased, fatigue, diarrhea, alopecia, vomiting, platelets 
> decreased, constipation, headache, and back pain.”

Source: [KISQALI: Prescribing information, page 12, captured 2026-11-13](https://www.novartis.com/us-en/sites/novartis_us/files/kisqali.pdf#page=12)

<a id="kisqali-side-effects-fulvestrant"></a>

### What are the side effects of Kisqali plus fulvestrant (MONALEESA-3)?

Applies to: Postmenopausal women with HR-positive, HER2-negative advanced or metastatic breast cancer and no or one prior line of endocrine therapy for advanced disease, with fulvestrant (MONALEESA-3)

> “The safety of KISQALI was evaluated in MONALEESA-3, a clinical trial of 724 postmenopausal women receiving KISQALI 
> plus fulvestrant or placebo plus fulvestrant [see Clinical Studies (14)]. The median duration of exposure to KISQALI plus 
> fulvestrant was 15.8 months with 58% of patients exposed for ≥ 12 months.”

Source: [KISQALI: Prescribing information, page 15, captured 2026-11-13](https://www.novartis.com/us-en/sites/novartis_us/files/kisqali.pdf#page=15)

> “The most common (≥ 20% on the KISQALI arm and ≥ 2% higher than placebo) adverse reactions, including laboratory 
> abnormalities, were leukocytes decreased, neutrophils decreased, lymphocytes decreased, creatinine increased, hemoglobin 
> decreased, gamma-glutamyl transferase increased, aspartate aminotransferase increased, nausea, alanine aminotransferase 
> increased, infections, platelets decreased, diarrhea, vomiting, constipation, glucose serum decreased, cough, rash, and 
> pruritus.”

Source: [KISQALI: Prescribing information, page 15, captured 2026-11-13](https://www.novartis.com/us-en/sites/novartis_us/files/kisqali.pdf#page=15)

<a id="kisqali-side-effects-premenopausal"></a>

### What are the side effects of Kisqali in premenopausal women (MONALEESA-7)?

Applies to: Pre- and perimenopausal women with HR-positive, HER2-negative advanced or metastatic breast cancer and no prior endocrine therapy for advanced disease, with a nonsteroidal aromatase inhibitor and goserelin (MONALEESA-7)

> “The safety data reported 
> below are based on 495 pre/perimenopausal patients receiving KISQALI plus NSAI plus goserelin or placebo plus NSAI 
> plus goserelin.”

Source: [KISQALI: Prescribing information, page 13, captured 2026-11-13](https://www.novartis.com/us-en/sites/novartis_us/files/kisqali.pdf#page=13)

> “The most common (≥ 20% on the KISQALI arm and ≥ 2% higher than placebo) adverse reactions, including laboratory 
> abnormalities, were leukocytes decreased, neutrophils decreased, hemoglobin decreased, lymphocytes decreased, gamma-
> glutamyl transferase increased, aspartate aminotransferase increased, infections, arthralgia, alanine aminotransferase 
> increased, nausea, platelets decreased, and alopecia.”

Source: [KISQALI: Prescribing information, page 13, captured 2026-11-13](https://www.novartis.com/us-en/sites/novartis_us/files/kisqali.pdf#page=13)

<a id="kisqali-serious-side-effects"></a>

### What serious or fatal side effects occurred with Kisqali in MONALEESA trials?

> “Serious adverse reactions occurred in 21% of patients who received KISQALI plus letrozole. Serious adverse reactions in 
> ≥ 1% of patients receiving KISQALI plus letrozole included abdominal pain (1.5%), vomiting (1.5%), constipation (1.2%), 
> nausea (1.2%), anemia (1.2%), febrile neutropenia (1.2%), dyspnea (1.2%), and alanine aminotransferase increased (1.2%).  
> Fatal adverse reactions occurred in 1.8% of patients who received KISQALI. Fatal adverse reactions in ≥ 0.1% of patients 
> receiving KISQALI included acute respiratory failure (0.6%), acute myocardial infarction, sudden death (with Grade 3 
> hypokalemia and Grade 2 QT prolongation), unknown cause, and pneumonia (0.3% each).”

Source: [KISQALI: Prescribing information, page 12, captured 2026-11-13](https://www.novartis.com/us-en/sites/novartis_us/files/kisqali.pdf#page=12)

> “Serious adverse reactions occurred in 17% of patients who received KISQALI plus NSAI plus goserelin. Serious adverse 
> reactions in ≥ 1% of patients receiving KISQALI plus NSAI plus goserelin included drug-induced liver injury (1.6%), 
> abdominal pain (1.2%), dyspnea (1.2%), febrile neutropenia (1.2%), and back pain (1.2%).”

Source: [KISQALI: Prescribing information, page 13, captured 2026-11-13](https://www.novartis.com/us-en/sites/novartis_us/files/kisqali.pdf#page=13)

> “Serious adverse reactions occurred in 29% of patients who received KISQALI plus fulvestrant. Serious adverse reactions in 
> ≥ 1% of patients receiving KISQALI plus fulvestrant included pneumonia (1.9%), nausea (1.4%), vomiting (1.4%), anemia 
> (1.2%), dyspnea (1.2%), neutropenia (1.2%). One case (0.2%) of fatal adverse reaction (pneumonia) occurred in patients 
> who received KISQALI plus fulvestrant.  
> Fatal adverse reactions occurred in 1.2% of patients who received KISQALI. Fatal adverse reactions in ≥ 0.1% of patients 
> receiving KISQALI included cardiac failure, ventricular arrhythmia, pneumonia, acute respiratory distress, pulmonary 
> embolism, and hemorrhagic shock (0.2% each).”

Source: [KISQALI: Prescribing information, page 15, captured 2026-11-13](https://www.novartis.com/us-en/sites/novartis_us/files/kisqali.pdf#page=15)

Note: The three passages are from the MONALEESA-2 (with letrozole), MONALEESA-7 (with a nonsteroidal aromatase inhibitor and goserelin), and MONALEESA-3 (with fulvestrant) safety sections of the Prescribing Information, in that order.

<a id="kisqali-discontinuation-rates"></a>

### How often did patients stop Kisqali for side effects in metastatic breast cancer trials?

> “Permanent discontinuation of 
> both KISQALI and letrozole due to an adverse reaction occurred in 7% of patients. Permanent discontinuation of KISQALI 
> alone occurred in 7% of patients. Adverse reactions which resulted in permanent discontinuation of both KISQALI and 
> letrozole in ≥ 2% of patients were alanine aminotransferase increased (5%), aspartate aminotransferase increased (3%), and 
> vomiting (2%).”

Source: [KISQALI: Prescribing information, page 12, captured 2026-11-13](https://www.novartis.com/us-en/sites/novartis_us/files/kisqali.pdf#page=12)

> “Permanent discontinuation of both KISQALI and NSAI due to an adverse reaction occurred in 3% of patients. Permanent 
> discontinuation of KISQALI alone occurred in 3% of patients. Adverse reactions which resulted in permanent 
> discontinuation of both KISQALI and NSAI in ≥ 2% of patients were alanine aminotransferase increased (2%), and 
> aspartate aminotransferase increased (2%).”

Source: [KISQALI: Prescribing information, page 13, captured 2026-11-13](https://www.novartis.com/us-en/sites/novartis_us/files/kisqali.pdf#page=13)

> “Permanent discontinuation of both KISQALI and fulvestrant due to an 
> adverse reaction occurred in 8% of patients. Permanent discontinuation of KISQALI alone occurred in 9% of patients. 
> Adverse reactions which resulted in permanent discontinuation of both KISQALI and fulvestrant in ≥ 2% of patients were 
> alanine aminotransferase increased (5%), and aspartate aminotransferase increased (3%).”

Source: [KISQALI: Prescribing information, page 15, captured 2026-11-13](https://www.novartis.com/us-en/sites/novartis_us/files/kisqali.pdf#page=15)

Note: The three passages are from the MONALEESA-2, MONALEESA-7, and MONALEESA-3 safety sections of the Prescribing Information, in that order.

<a id="kisqali-dose-reduction-rates"></a>

### How often was the Kisqali dose reduced for side effects in MONALEESA trials?

> “Dose reductions of KISQALI due to an adverse reaction occurred in 45% of patients receiving KISQALI plus letrozole. 
> Adverse reactions which required dose reductions in ≥ 2% of patients included neutropenia (24%), neutrophils decreased 
> (8%), and alanine aminotransferase increased (3%).”

Source: [KISQALI: Prescribing information, page 12, captured 2026-11-13](https://www.novartis.com/us-en/sites/novartis_us/files/kisqali.pdf#page=12)

> “Dose reductions of KISQALI due to an adverse reaction occurred in 33% of patients receiving KISQALI plus NSAI plus 
> goserelin. Adverse reactions which required dose reductions in ≥ 2% of patients included neutropenia (17%), neutrophils 
> decreased (5%), and alanine aminotransferase increased (2%).”

Source: [KISQALI: Prescribing information, page 13, captured 2026-11-13](https://www.novartis.com/us-en/sites/novartis_us/files/kisqali.pdf#page=13)

> “Dose reductions of KISQALI due to an adverse reaction occurred in 32% of patients receiving KISQALI plus fulvestrant. 
> Adverse reactions which required dose reductions in ≥ 2% of patients included neutropenia (15%), and neutrophils 
> decreased (3%).”

Source: [KISQALI: Prescribing information, page 15, captured 2026-11-13](https://www.novartis.com/us-en/sites/novartis_us/files/kisqali.pdf#page=15)

Note: The three passages are from the MONALEESA-2, MONALEESA-7, and MONALEESA-3 safety sections of the Prescribing Information, in that order.

## Warnings

<a id="kisqali-lung-problems"></a>

### Can Kisqali cause lung problems (ILD or pneumonitis)?

> “Severe, life-threatening, or fatal interstitial lung disease (ILD) and/or pneumonitis can occur in patients treated with 
> KISQALI and other CDK 4/6 inhibitors.”

Source: [KISQALI: Prescribing information, page 7, captured 2026-11-13](https://www.novartis.com/us-en/sites/novartis_us/files/kisqali.pdf#page=7)

> “In patients with advanced or metastatic breast cancer (MONALEESA-2, MONALEESA-3, MONALEESA-7), 1.6% of 
> patients had ILD/pneumonitis (any Grade, 0.4% had Grade 3-4, and 0.1% had a fatal outcome). Additional cases of 
> ILD/pneumonitis have occurred in the postmarketing setting, some resulting in death [see Adverse Reactions (6.2)]. 
> Monitor patients for pulmonary symptoms indicative of ILD/pneumonitis which may include hypoxia, cough, and dyspnea. 
> In patients who have new or worsening respiratory symptoms suspected to be due to ILD or pneumonitis, interrupt 
> KISQALI immediately and evaluate the patient. Permanently discontinue KISQALI in patients with severe 
> ILD/pneumonitis or any recurrent symptomatic ILD/pneumonitis. [see Dosage and Administration (2.2)].”

Source: [KISQALI: Prescribing information, page 8, captured 2026-11-13](https://www.novartis.com/us-en/sites/novartis_us/files/kisqali.pdf#page=8)

> “INTERSTITIAL LUNG DISEASE/PNEUMONITIS
>
> Grade 1 (asymptomatic)
>
>
>
> No dose interruption or adjustment is required
>
> Initiate appropriate medical therapy and monitor as clinically indicated 
>
>
>
>
> Grade 2 (symptomatic)
>
>
>
> Interrupt dose until recovery to grade ≤1, then consider resuming KISQALI at the next lower dose level
>
> If grade 2 recurs, discontinue
>
>
>
>
> Grade 3 (severe symptomatic) or grade 4 (life threatening)
>
>
>
> Discontinue
>
>
>
>
> For grade 2 ILD/pneumonitis, an individualized benefit-risk assessment should be performed when considering resuming KISQALI
>
> ILD, interstitial lung disease.”

Source: [KISQALI: Dose Adjustments | mBC | KISQALI® (ribociclib) | HCP, captured 2026-11-13](https://www.kisqali-hcp.com/metastatic-breast-cancer/assessments-and-dosing/dose-adjustments#:~:text=INTERSTITIAL%20LUNG%20DISEASE%2FPNEUMONITIS,ILD%2C%20interstitial%20lung%20disease.)

This passage is in a collapsed section of the page; select: INTERSTITIAL LUNG DISEASE/PNEUMONITIS

Note: The last passage is the dose adjustment guidance for ILD/pneumonitis on the dose adjustments page of the Kisqali HCP site.

<a id="kisqali-qt-prolongation"></a>

### Does Kisqali cause QT prolongation or heart rhythm problems?

> “KISQALI has been shown to prolong the QT interval in a concentration-dependent manner [see Clinical Pharmacology 
> (12.2)].  
> Avoid KISQALI in patients who are at significant risk of developing Torsades de Pointes (TdP), including those with:  
> • 
> congenital long QT syndrome; 
> • 
> uncontrolled or significant cardiac disease, recent myocardial infarction, heart failure, unstable angina, 
> bradyarrhythmias, uncontrolled hypertension, high degree atrioventricular block, severe aortic stenosis, or uncontrolled 
> hypothyroidism; 
> • 
> electrolyte abnormalities;  
> • 
> taking drugs known to prolong QT interval and/or strong CYP3A inhibitors as this may lead to prolongation of the 
> QTcF interval.”

Source: [KISQALI: Prescribing information, page 8, captured 2026-11-13](https://www.novartis.com/us-en/sites/novartis_us/files/kisqali.pdf#page=8)

> “In patients with advanced or metastatic breast cancer (MONALEESA-2, MONALEESA-3, and MONALEESA-7) who 
> received 600 mg KISQALI plus NSAI or fulvestrant, 15 out of 1054 patients (1.4%) had a > 500 ms post-baseline QTcF 
> value and 61 out of 1054 patients (6%) had a > 60 ms QTcF increase from baseline. QTcF prolongation was reversible with 
> dose interruption. The majority of QTcF prolongation occurred within the first four weeks of KISQALI. There were no 
> reported cases of Torsades de Pointes.  
> In MONALEESA-2, in the KISQALI plus letrozole treatment arm, there was one (0.3%) sudden death in a patient with 
> Grade 3 hypokalemia and Grade 2 QT prolongation. No cases of sudden death were reported in MONALEESA-7 or 
> MONALEESA-3 [see Adverse Reactions (6)].”

Source: [KISQALI: Prescribing information, page 8, captured 2026-11-13](https://www.novartis.com/us-en/sites/novartis_us/files/kisqali.pdf#page=8)

> “Perform ECG in all patients prior to starting KISQALI. Initiate treatment with KISQALI only in patients with QTcF values 
> less than 450 ms. Repeat ECG at approximately Day 14 of the first cycle, and as clinically indicated.”

Source: [KISQALI: Prescribing information, page 8, captured 2026-11-13](https://www.novartis.com/us-en/sites/novartis_us/files/kisqali.pdf#page=8)

<a id="kisqali-qt-by-trial"></a>

### How common is QT prolongation with Kisqali in each MONALEESA trial?

> “Data are from a pooled analysis of 1054 premenopausal and postmenopausal patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) metastatic breast cancer (mBC) who were treated with KISQALI + an aromatase inhibitor (AI) or fulvestrant in the first- or second-line (1L/2L) across the MONALEESA-2, MONALEESA-3, and MONALEESA-7 trials.<sup>4</sup>
>
> In the pooled analysis<sup>4</sup>:
>
> 1.4% of patients had a >500 ms postbaseline QTcF value 
>
> 6% experienced a >60 ms increase from baseline in QTcF interval 
>
> There were no reported cases of torsades de pointes 
>
> In each MONALEESA trial: 
>
> MONALEESA-2 (KISQALI + AI in 1L postmenopausal patients): <1% of patients had a >500 ms postbaseline QTcF value, and 3% experienced a >60 ms increase from baseline in QTcF interval. There was 1 (0.3%) sudden death in a patient with grade 3 hypokalemia and grade 2 QT prolongation<sup>1,4</sup>
>
> MONALEESA-3 (KISQALI + fulvestrant in 1L/2L postmenopausal patients): 2% of patients had a >500 ms postbaseline QTcF value, and 7% experienced a >60 ms increase from baseline in QTcF interval. No cases of sudden death were reported<sup>2</sup>
>
> MONALEESA-7 (KISQALI + AI in 1L premenopausal patients): The number of patients who had a >500 ms postbaseline QTcF value was not reached, and 7% experienced a >60 ms increase from baseline in QTcF interval. No cases of sudden death were reported<sup>3</sup>”

Source: [KISQALI: FAQs | mBC | KISQALI® (ribociclib) | HCP, captured 2026-11-13](https://www.kisqali-hcp.com/metastatic-breast-cancer/videos-resources-and-faqs/faqs#:~:text=Data%20are%20from%20a%20pooled,baseline%20in%20QTcF%20interval.%20No%20cases%20of%20sudden%20death%20were)

On the page, select: How common is QT prolongation with KISQALI in metastatic breast cancer?

<a id="kisqali-liver-problems"></a>

### Can Kisqali cause liver problems?

> “In patients with advanced or metastatic breast cancer (MONALEESA-2, MONALEESA-7 and MONALEESA-3) treated 
> with KISQALI Grade 3 or 4 increases in ALT and AST occurred in 11% and 8%, respectively. Among the patients who had 
> Grade ≥ 3 ALT/AST elevation, the median time-to-onset was 92 days for the KISQALI plus aromatase inhibitor or 
> fulvestrant treatment arms. The median time to resolution to Grade ≤ 2 was 21 days in the KISQALI plus aromatase 
> inhibitor or fulvestrant treatment arms. In MONALEESA-2 and MONALEESA-3, concurrent elevations in ALT or AST 
> greater than three times the ULN and total bilirubin greater than two times the ULN, with normal alkaline phosphatase, in 
> the absence of cholestasis (Hy’s Law) occurred in 6 (1%) patients and all patients recovered after discontinuation of 
> KISQALI.”

Source: [KISQALI: Prescribing information, page 9, captured 2026-11-13](https://www.novartis.com/us-en/sites/novartis_us/files/kisqali.pdf#page=9)

> “Perform liver function tests (LFTs) in all patients before initiating KISQALI. Monitor LFTs every 2 weeks for first 2 cycles, 
> at the beginning of each of the subsequent 4 cycles, and as clinically indicated [see Dosage and Administration (2.2)].”

Source: [KISQALI: Prescribing information, page 9, captured 2026-11-13](https://www.novartis.com/us-en/sites/novartis_us/files/kisqali.pdf#page=9)

<a id="kisqali-neutropenia"></a>

### Does Kisqali cause neutropenia (low white blood cell counts)?

> “KISQALI causes concentration-dependent neutropenia.”

Source: [KISQALI: Prescribing information, page 9, captured 2026-11-13](https://www.novartis.com/us-en/sites/novartis_us/files/kisqali.pdf#page=9)

> “In patients with advanced or metastatic breast cancer (MONALEESA-2, MONALEESA-7, and MONALEESA-3) who 
> received KISQALI plus NSAI or fulvestrant, 75% had neutropenia, 62% had Grade 3 or 4 decrease in neutrophil count 
> (based on laboratory findings), and 1.7% had febrile neutropenia. The median time to Grade ≥ 2 neutropenia was 17 days. 
> The median time to resolution of Grade ≥ 3 neutropenia to Grade < 3 was 12 days. Treatment discontinuation due to 
> neutropenia was required in 1% of patients.”

Source: [KISQALI: Prescribing information, page 9, captured 2026-11-13](https://www.novartis.com/us-en/sites/novartis_us/files/kisqali.pdf#page=9)

> “Perform a complete blood count (CBC) in all patients before initiating KISQALI. Monitor CBC every 2 weeks for the first 2 
> cycles, at the beginning of each subsequent 4 cycles, and as clinically indicated.”

Source: [KISQALI: Prescribing information, page 9, captured 2026-11-13](https://www.novartis.com/us-en/sites/novartis_us/files/kisqali.pdf#page=9)

## Monitoring

<a id="kisqali-monitoring"></a>

### What lab tests and monitoring are needed with Kisqali?

> “Routine monitoring for lab abnormalities<sup>1</sup>
>
> Blood tests are performed at baseline, on Day 14 of Cycle 1, on Days 1 and 14 of Cycle 2, on Day 1 of Cycles 3 through 6, and as clinically indicated
>
> For LFTs, if grade ≥2 abnormalities are noted, more frequent monitoring is recommended
>
> Correct any electrolyte abnormalities prior to treatment
>
> Additional monitoring may be required as clinically indicated”

Source: [KISQALI: Scheduled Assessments | mBC | KISQALI® (ribociclib) | HCP, captured 2026-11-13](https://www.kisqali-hcp.com/metastatic-breast-cancer/assessments-and-dosing/scheduled-assessments#:~:text=Routine%20monitoring%20for%20lab,be%20required%20as%20clinically%20indicated)

> “2 required ECG assessments completed within the first 2 weeks of treatment<sup>1</sup>
>
> ECGs are performed at baseline, on Day 14 of Cycle 1, and as clinically indicated
>
> KISQALI should only be initiated in patients with QTcF <450 ms
>
> In case of QTcF prolongation during therapy, more frequent assessments are recommended”

Source: [KISQALI: Scheduled Assessments | mBC | KISQALI® (ribociclib) | HCP, captured 2026-11-13](https://www.kisqali-hcp.com/metastatic-breast-cancer/assessments-and-dosing/scheduled-assessments#:~:text=2%20required%20ECG%20assessments%20completed,more%20frequent%20assessments%20are%20recommended)

<a id="kisqali-baseline-tests"></a>

### What tests are needed before starting Kisqali?

> “Baseline assessments—complete blood count (CBC), liver function tests (LFTs), electrolytes, electrocardiagrams (ECGs)—are required before initiating treatment with KISQALI<sup>®</sup> (ribociclib). Correct any electrolyte abnormalities prior to treatment.<sup>1</sup>”

Source: [KISQALI: FAQs | mBC | KISQALI® (ribociclib) | HCP, captured 2026-11-14](https://www.kisqali-hcp.com/metastatic-breast-cancer/videos-resources-and-faqs/faqs#:~:text=Baseline%20assessments%E2%80%94complete%20blood%20count%20%28CBC%29%2C,any%20electrolyte%20abnormalities%20prior%20to)

This passage is in a collapsed section of the page; select: What assessments and monitoring are required for treatment with KISQALI?

> “KISQALI should only be initiated in patients with QT interval corrected by Fridericia's formula (QTcF) <450 ms.”

Source: [KISQALI: FAQs | mBC | KISQALI® (ribociclib) | HCP, captured 2026-11-14](https://www.kisqali-hcp.com/metastatic-breast-cancer/videos-resources-and-faqs/faqs#:~:text=KISQALI%20should%20only%20be%20initiated,Fridericia%27s%20formula%20%28QTcF%29%20%3C450%20ms.)

This passage is in a collapsed section of the page; select: What assessments and monitoring are required for treatment with KISQALI?

## Related pages
- [Medical information: Kisqali (ribociclib): HR-positive HER2-negative advanced or metastatic breast cancer](https://www.evicenter.com/medical-information/kisqali--hr-positive-her2-negative-advanced-or-metastatic-breast-cancer)
- [Indication](https://www.evicenter.com/medical-information/kisqali--hr-positive-her2-negative-advanced-or-metastatic-breast-cancer/indication)
- [Clinical trials](https://www.evicenter.com/medical-information/kisqali--hr-positive-her2-negative-advanced-or-metastatic-breast-cancer/clinical-trials)
- [Specific populations](https://www.evicenter.com/medical-information/kisqali--hr-positive-her2-negative-advanced-or-metastatic-breast-cancer/specific-populations)
- [Drug interactions](https://www.evicenter.com/medical-information/kisqali--hr-positive-her2-negative-advanced-or-metastatic-breast-cancer/drug-interactions)
- [Dosing and administration](https://www.evicenter.com/medical-information/kisqali--hr-positive-her2-negative-advanced-or-metastatic-breast-cancer/dosing-and-administration)
- [Access and coverage](https://www.evicenter.com/medical-information/kisqali--hr-positive-her2-negative-advanced-or-metastatic-breast-cancer/access-and-coverage)
- [Guidelines](https://www.evicenter.com/medical-information/kisqali--hr-positive-her2-negative-advanced-or-metastatic-breast-cancer/guidelines)
